Risk factor
Low price volatility
Profitability factor
Greatly undervalued vs peers
About
SRA Holdings, Inc., established in Tokyo, Japan, in 1991, operates as a global technology firm with a focus on three primary business segments: the creation of advanced IT systems, the ongoing management and administration of these systems, and the strategic promotion of a variety of product solutions. The company's system development capabilities are extensive, covering bespoke solutions for the financial sector, embedded technologies, academic institutions, and general business functions, along with infrastructure development and expert consulting services. Within its operation and administration segment, SRA Holdings offers crucial outsourcing, infrastructure management, and comprehensive system operational support. The product solutions division markets a wide array of technological tools, addressing needs from internal controls and cloud security to artificial intelligence, business intelligence, open-source software, academic applications, development support, system quality enhancement, and healthcare services. Key among its specific solution offerings are Cavirin Pulsar, a powerful compliance and security platform tailored for hybrid cloud settings; UniVision, a comprehensive, web-based university administration system integrating various academic tools such as Student Portfolio and DB Spiral; PowerGres, providing tools and support for efficient database operations; and HEALTHPLAYER, a specialized platform for collecting and analyzing diverse healthcare data. Additional solutions include P-Con, a paperless system designed to digitize existing physical documents; MailDepot, a dedicated email archiving product; ProjDepot, which facilitates integrated project management across an organization; TestDepot, an embedded software development tool that automates testing processes; and Testablish, offering automated testing for graphical user interface applications.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT